Abstract:Research and development on Nectin-4 antibody-drug conjugates (ADC) have been greatly accelerated since the approval of enfortumab vedotin to treat uroepithelial cancer. During the course of this study, we identified that autophagy serves as a cytoprotective mechanism during Nectin-4-MMAE treatment and proposed a strategy to enhance the antitumor effects of Nectin-4-MMAE in bladder cancer. Nectin-4-MMAE rapidly internalized into bladder cancer cells in 30 minutes and released MMAE, inducing the onset of caspase-mediated apoptosis and leading to the inhibition of tumor cell growth. Transcriptomics showed significant alterations in autophagy-associated genes in bladder cancer cells treated with Nectin-4-MMAE, which suggested autophagy was activated by Nectin-4-MMAE. Furthermore, autophagy activation was characterized by ultrastructural analysis of autophagosome accumulation, immunofluorescence of autophagic flux, and immunoblotting autophagy marker proteins SQSTM1 and LC3 I/II. Importantly, inhibiting autophagy by LY294002 and chloroquine significantly enhances the cytotoxicity effects of Nectin-4-MMAE in bladder cancer cells. Additionally, we detected the participation of the AKT/mTOR signaling cascade in the induction of autophagy by Nectin-4-MMAE. The combination of Nectin-4-MMAE and an autophagy inhibitor demonstrated enhanced antitumor effects in the HT1376 xenograft tumor model. After receiving a single dose of Nectin-4-MMAE, the group that received the combination treatment showed a significant decrease in tumor size compared to the group that received only one type of treatment. Notably, one mouse in the combination treatment group achieved complete remission of the tumor. The combination group exhibited a notable rise in apoptosis and necrosis, as indicated by H&E staining and immunohistochemistry (cleaved caspase-3, ki67). These findings demonstrated the cytoprotective role of autophagy during Nectin-4-MMAE treatment and highlighted the potential of combining Nectin-4-MMAE with autophagy inhibitors for bladder cancer treatment.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to enhance the anti - tumor effect of Nectin - 4 - MMAE in the treatment of bladder cancer by suppressing autophagy. Specifically, the researchers found that Nectin - 4 - MMAE (an antibody - drug conjugate targeting Nectin - 4) can induce autophagy during the treatment process, and this autophagy has a protective effect on tumor cells. Therefore, they proposed a strategy, that is, to improve the anti - tumor effect of Nectin - 4 - MMAE by suppressing autophagy. ### Main research contents: 1. **Cytotoxicity of Nectin - 4 - MMAE**: - The researchers first evaluated the cytotoxicity of Nectin - 4 - MMAE on Nectin - 4 - positive bladder cancer cells (such as HT1376 and SW780). The results showed that Nectin - 4 - MMAE exhibited significant dose - dependent cytotoxicity in these cells, while it had almost no toxicity in Nectin - 4 - negative cells (such as 5637 and T24). 2. **Internalization process of Nectin - 4 - MMAE**: - Through fluorescently labeled Nectin - 4 - MMAE, the researchers observed that the drug could be rapidly internalized into cells within 30 - 60 minutes and co - localized with lysosomes, indicating that it could be effectively taken up by cells and transported to lysosomes for degradation. 3. **Autophagy induced by Nectin - 4 - MMAE**: - Through transcriptome analysis, the researchers found that the expression of autophagy - related genes was significantly up - regulated after Nectin - 4 - MMAE treatment. Further experiments (such as transmission electron microscopy, immunofluorescence and Western blot) confirmed that Nectin - 4 - MMAE could induce the formation of autophagosomes and the activation of autophagic flux. 4. **Molecular mechanism of autophagy**: - The researchers found that Nectin - 4 - MMAE induces autophagy by inhibiting the Akt/mTOR signaling pathway. The phosphorylation level of the Akt/mTOR pathway was significantly decreased after Nectin - 4 - MMAE treatment, which may be a key mechanism for autophagy induction. 5. **Inhibiting autophagy enhances the anti - tumor effect of Nectin - 4 - MMAE**: - By using autophagy inhibitors (such as LY294002 and chloroquine), the researchers found that inhibiting autophagy could significantly enhance the cytotoxicity and apoptosis - inducing ability of Nectin - 4 - MMAE. In in - vivo experiments, the combined use of Nectin - 4 - MMAE and autophagy inhibitors significantly reduced the tumor volume and, in some cases, achieved complete remission. ### Conclusion: This study reveals that Nectin - 4 - MMAE protects tumor cells by inducing autophagy, and inhibiting autophagy can significantly enhance the anti - tumor effect of Nectin - 4 - MMAE. This finding provides a new strategy for improving the efficacy of Nectin - 4 - MMAE in the treatment of bladder cancer.

A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE

The Cytoprotective Role Of Gemcitabine-Induced Autophagy Associated With Apoptosis Inhibition In Triple-Negative Mda-Mb-231 Breast Cancer Cells

Targeted Therapeutic Strategies for Nectin-4 in Breast Cancer: Recent Advances and Future Prospects

Sodium Butyrate Inhibits Migration and Induces AMPK-mTOR Pathway-Dependent Autophagy and ROS-mediated Apoptosis Via the Mir-139-5p/bmi-1 Axis in Human Bladder Cancer Cells.

Echinatin Inhibits Tumor Growth and Synergizes with Chemotherapeutic Agents Against Human Bladder Cancer Cells by Activating P38 and Suppressing Wnt/β-catenin Pathways

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.

Enhancing antitumor efficacy of CLDN18.2-directed antibody-drug conjugates through autophagy inhibition in gastric cancer

Autophagy flux in bladder cancer: Cell death crosstalk, drug and nanotherapeutics

AMPK-mTOR-ULK1 axis activation-dependent autophagy promotes hydroxycamptothecin-induced apoptosis in human bladder cancer cells

Inducing mitochondriopathy-like damages by transformable nucleopeptide nanoparticles for targeted therapy of bladder cancer

A tumor targeted nano micelle carrying astragaloside IV for combination treatment of bladder cancer

An Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived&nbsp;Mimetic Nanovesicles to Treat Bladder Cancer

Synergy of Tumor Microenvironment Remodeling and Autophagy Inhibition to Sensitize Radiation for Bladder Cancer Treatment.

Immunotherapy Strategy Targeting Programmed Cell Death Ligand 1 and CD73 with Macrophage-Derived Mimetic Nanovesicles to Treat Bladder Cancer

Modulating autophagy to boost the antitumor efficacy of TROP2-directed antibody-drug conjugate in pancreatic cancer

Intravesical In Situ Immunostimulatory Gel for Triple Therapy of Bladder Cancer

Autophagy Inhibition Sensitizes Bladder Cancer Cells to the Photodynamic Effects of the Novel Photosensitizer Chlorophyllin E4.

Inhibition of autophagy can promote the apoptosis of bladder cancer cells induced by SC66 through the endoplasmic reticulum stress pathway

Anti-Proliferative Effects of Lidocaine as an Autophagy Inducer in Bladder Cancer via Intravesical Instillation: In Vitro and Xenograft Mouse Model Experiments

Pectolinarigenin inhibits bladder urothelial carcinoma cell proliferation by regulating DNA damage/autophagy pathways

Targeting the anaphase-promoting complex/cyclosome (APC/C) enhanced antiproliferative and apoptotic response in bladder cancer